John Baird, M.D.

800-826-4673
John Baird, M.D.
Hematologist-Oncologist
Clinical Expertise
  • Lymphoma
  • Leukemia
  • Bone Marrow and Stem Cell Transplant
Research Area
  • Immunotherapies for Leukemia and Lymphoma
Academic Appointments
  • Assistant Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Leukemia
Lymphoma

John H. Baird, M.D., was drawn to his career as a doctor when he found working with patients to be his favorite part of his initial focus in biomedical engineering. For him, being a physician-researcher is the best of both worlds. He provides innovative therapies and his own brand of compassionate care to people with leukemia and lymphoma, while also advancing the state of the field in cancer treatment and improving patient outcomes with clinical research.

Dr. Baird pursued his medical training at the University of Arkansas, then served as an intern and resident at the University of Pennsylvania and a fellow at Stanford University, where he specialized in medical oncology, hematology, and blood and marrow transplantation. His research concerns next-generation cellular therapies for blood diseases, including CAR T cell therapy, in which a patient's own immune cells are engineered to seek and destroy cancer.

Location

Education & Experience

Board Certifications

  • Hematology
  • Medical Oncology
  • Internal Medicine

Degrees

  • 2013, M.D., University of Arkansas for Medical Sciences, Little Rock, AR
  • 2008, B.S., Biomedical Engineering, Washington University, St. Louis, MO

Fellowship

  • 2020–2021, Fellow, Blood and Marrow Transplantation, Stanford Hospital & Clinics, Palo Alto, CA
  • 2019–2020, Postdoctoral Fellow, Cancer Cellular Therapies, Stanford University, Palo Alto, CA
  • 2016–2019, Fellow, Hematology and Medical Oncology, Stanford Hospital & Clinics, Palo Alto, CA

Residency

  • 2014–2016, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

Internship

  • 2013–2014, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

Professional Experience

  • 2021–Present, Assistant Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope®, Duarte, CA

Awards & Memberships

Awards

  • 2023 CIRM CLIN2 Grant, City of Hope
  • 2022, Lymphoma SPORE Career Enhancement Award, City of Hope
  • 2020, Abstract Achievement Award, American Society of Hematology
  • 2019, NIH T32 Institutional Training Grant, Stanford, Department of BMT
  • 2013, Richard V. Ebert Award, UAMS, Department of Internal Medicine
  • 2013, Graduated with Honors in Research, UAMS
  • 2012, Class of 1949 Scholarship, UAMS
  • 2012, Clinical Research Training Program Fellow, NIH-OCRTME
  • 2011, Alpha Omega Alpha, UAMS
  • 2010, Barton Foundation Scholarship, UAMS
  • 2010, Dr. George S. Wise Memorial Scholarship, UAMS
  • 2009, Class of 1954 Scholarship, UAMS
  • 2009, Medical Student Research Program in Diabetes, NIDDK
  • 2008, Medical Alumni Association Scholarship, UAMS
  • 2008, Dorothy Snider Foundation Scholarship, UAMS
  • 2003, Eagle Scout, Bronze and Gold Eagle Palms, BSA QAC Troop 7

Memberships

  • American Association for Cancer Research
  • American Society of Hematology
  • American Society for Transplantation and Cellular Therapy
  • American Society of Clinical Oncology
  • CIBMTR Infection and Immune Reconstitution Working Group
  • American College of Physicians

Publications

  • Ghobadi A, Anagnostou T, Azzi J, Hamadani M, Logan B, Ahmed S, Bharadwaj S, Baird JH, Jacobson C, Locke FL, Ulrickson M, Reagan PM, Hemmer MT, Hu ZH, Luo ZC, Wang HL, Jung AS, Nahas M, Best T, Beygi S, Pasquini MC. Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis. Transplant Cell Ther. 2026 Jan 10:S2666-6367(26)00022-9. doi: 10.1016/j.jtct.2026.01.010. Epub ahead of print. PMID: 41525947.
  • Frank MJ*, Baird JH*, et al.: “CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy.” N Engl J Med. 2023; in submission.
  • Ong SY, Baird JH: “A primer on chimeric antigen receptor T-cell therapy-related toxicities for the intensivist.” J Intensive Care Med. 2023; accepted.
  • Ong SY, Pak S, Mei M…Baird JH, et al.: “Bendamustine is a well-tolerated alternative to fludarabine as lymphodepletion for standard of care CD19-directed chimeric antigen receptor (CAR) T-cell therapy.” Am J Hematol. 2023; accepted.
  • Nie EH, Su YJ, Baird JH, et al.: “Radiographic and clinical correlatives associated with immune effector cell-associated neurotoxicity syndrome (ICANS) after CD19 CAR T-cell therapy for mantle cell lymphoma.” Neuro-Oncology. 2023; in submission.
  • Harris CE, Vijenthira A, Ong SY…Baird JH: “COVID-19 and other viral infections in patients with hematologic malignancies.” Am Soc Clin Oncol Educ Book. 2023; 43:e390778.
  • Ladbury C, Dandapani S…Baird JH, et al.: “Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed/refractory large B-cell lymphoma.” Cancers (Basel). 2023; 15(6):1747.
  • Sworder BJ, Kurtz DM, Alig SKC…Baird JH, et al.: “Determinants of resistance to engineered T-cell therapies targeting CD19 in large B-cell lymphomas.” Cancer Cell. 2022; 41(1):210-225.e5.
  • Good Z, Spiegel JY, Sahaf B…Baird JH, et al.: “Post-infusion TReg-like CAR T cells identify patients resistant to CD19-CAR therapy.” Nat Med. 2022; 28(9):1860-71.
  • Rainone M, Ngo D, Baird JH, et al.: “Emapalumab for CART-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis.” Blood Adv. 2023; 7(4):533-36.
  • Baird JH, Frank MJ, Craig J, et al.: “CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma.” Blood. 2021; doi: 10.1182/blood.2020009432.
  • Spiegel JY, Patel S, Muffly L, Hossain N, Oak J, Baird JH, et al.: “CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.” Nat Med. 2021; 27(8):1419-31
  • Johnsrud AJ, Craig J, Baird JH, et al. “Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T cell therapy.” Blood Adv. 2021; doi: 10.1182/bloodadvances.2021004716.
  • Baird JH, Epstein DJ, Tamaresis JS, et al.: “Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.” Blood Adv. 2021; 5(1):143-55.
  • Van Vuren AJ, Minniti CP, Mendelsohn L, Baird JH, et al.: “Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in SCD.” Am J
  • Baird JH, Gotlib J, George TI, et al.: “A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.” Blood Adv. 2019 Aug 13;3(15):2264-2271.
  • Baird JH, Gotlib J: “Clinical validation of KIT inhibition in advanced systemic mastocytosis.” Curr Hematol Malig Rep. 2018 Oct;13(5):407-416.
  • Baird JH, Minniti CP, Lee JM, Tian X, et al.: “Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide.” Br. J. Haematol. 2015; 168(5):737-46. 7.
  • Baird JH, Frey N, Birnbaum B, Porter DL: “Voriconazole-induced periostitis after allogeneic stem cell transplantation.” Am. J. Hematol. 2015; 90(6):574-5.
  • Lodhi IJ, Yin L, Coleman T, Baird JH, et al.: “Targeted inhibition of adipose lipogenesis decreases obesity and insulin resistance by disrupting PPAR-γ activation.” Cell Metab. 2012; 16(2):189-201.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
4.9
Recommend this provider office
4.9
Show respect for what you say
4.9
Spend enough time with you
4.9
Rate provider 0-10
4.8
Provider explain in way you understand
4.8
Provider listen carefully to you
4.8
Know important info medical history
04/25/26
Would highly recommend the City of Hope to those in need of treatment for cancer. - Verified patient
04/25/26
I have noting but excellent things to say about Dr. Baird. Having to go through this life threatening medical condition is difficult enough on one's own but with him as my oncologist, I could not have been more fortunate. His communicative skills, knowledge and compassion is one of the main reasons I believe I made it through to remission. - Verified patient
01/23/26
There isn't a better doctor for both care and compassion than Dr. Baird. I've seen more than my share of doctors in the past 2 years, and he is far better than ALL others! - Verified patient
01/15/26
All the staff showed excellent care and cooperation together. - Verified patient
11/28/25
Dr. Baird asked us as many questions as we asked him. He seemed to genuinely care about us and our illness and how we have been navigating the process. - Verified patient